Santaris Pharma A/S forms strategic alliance with Shire plc to develop RNA-based medicines for the treatment of rare genetic disorders 

• Santaris Pharma A/S and Shire plc to engage in a multi-year research program utilizing Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against certain targets for the treatment of rare genetic disorders
   
• Santaris Pharma A/S to receive significant upfront payments, milestone payments and royalties  for providing access to its LNA technology, exclusivity for three pre-defined targets and funding for discovery 
  
• Partnership for the treatment of rare genetic disorders further demonstrates versatility of the LNA Drug Platform to develop RNA-based medicines for a range of disease areas including metabolic disorders, cancer, infectious and inflammatory diseases 

Hoersholm, Denmark, August 24, 2009

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders. 

The alliance will use Santaris Pharma A/S’ proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against certain targets.  Shire will be responsible for the selection of appropriate drug candidates, as well as further development and commercialization of products arising from the alliance. 

Under the terms of the agreement Santaris Pharma A/S will receive initial early stage payments of $6.5 million covering technology access, exclusivity for three pre-defined targets and initial discovery funding, and an additional early stage payment of $13.5 million upon successful completion of certain initial studies. The initial term of the research collaboration is two years; Shire has an option to extend for up to two additional years.  

Article in FierceBiotech click here.

Article in Business.dk click here (Danish only).

July 8th, 2009
Nanoradio has secured 12.5 MEUR, and brings in 2 new investors to strengthen Nanoradio's competitiveness.

Nanoradio today announced that they have signed an agreement with two new investors, Viking Venture and Creandum, who together with the current investors, Ferd Venture, Industrifonden, Innovacom, Nordic Venture Partners, Teknoinvest will fund Nanoradio through its growth phase.

The Nanoradio "Always On Wi-Fi"TM solution - the NRX700/2 Wi-Fi chipset, which offers fully tested 802.11b/g functionality, featuring ultra-low power consumption, has won tremendous customer attraction. With the new investment, Nanoradio will be well equipped to support its volume growth together with a more ambitious launch plan of a new line of competitive products.

(Nanoradio's homepage)

For the whole press release click here.

BioForm Medical Receives FDA Approval for Mixing Lidocaine With RADIESSE(r) Dermal Filler

SAN MATEO, Calif., Jul 16, 2009
BioForm Medical, Inc. (Nasdaq:BFRM) today announced U.S. Food and Drug Administration (FDA) approval for a method of mixing RADIESSE(r) dermal filler with lidocaine, which, in clinical trials, has demonstrated an improvement in patient comfort and an increase in patient satisfaction with RADIESSE dermal filler procedures. BioForm Medical will immediately begin commercial efforts to educate physicians to use this method of mixing RADIESSE dermal filler with lidocaine.

(BioForm's homepage)  

Affitech successfully closed directed offering and received gross proceeds in cash of DKK 26.8 million

Summary:
Affitech have closed the directed offering and received gross proceeds in cash
of DKK 26.8 million. The offering consisted of 133,476,364 shares issued
against contribution in kind shares in Affitech Research AS (former Affitech
AS) and 34,366,225 shares issued against cash payment of the market value of
DKK 0.78 per share of DKK 0.50 directed against certain investors who have
precomitted to subscribe for the shares. The issuance of shares has been
registered at the Danish Commerce and Companies' Agency and Affitech's Articles
of Association have been changed accordingly.
The cash offering of 34,366,225 shares was carried out as a private placement
at market price of DKK 0.78 per share of DKK 0.50 without preemptive rights to
the existing shareholders. The subscription period for the shares issued
against cash payment commenced on June 30, 2009 at 9.00 a.m. CET and closed on
July 1, 2009 at 5.00 p.m. CET. Payment was made during the subscription period.

The Offering was not underwritten, but Ferd AS, Arendals Fossekompani ASA,
Braganza AS, Teknoinvest VII KS, Verdane Capital IV TWIN AS, Anchor Secondary 3
Holding AS, Sarsia Life Science Fund AS, Glastad Invest AS, Lene AS, Hans
Bjarne Dahl, John McDougall, Kerstin Maria Hareide, Marike Stassar and Amino AS
had undertaken a binding pre-commitment to the company to subscribe for cash
shares for a total investment of DKK 26.8 million, corresponding to 100% of the
cash offering.

The newly issued shares are expected to be admitted to trading and official
listing on the NASDAQ OMX on July 6, 2009 under the ISIN of the existing
shares.


Hørsholm, July 2, 2009